← Back to Search

Behavioural Intervention

Resistance Training + Protein Supplementation for Pancreatic Cancer

N/A
Recruiting
Led By Christina M Dieli-Conwright, PhD, MPH
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Speak English or Spanish
Non-metastatic pancreatic cancer patients initiating neoadjuvant chemotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up evaluating change between baseline, mid-intervention, and post-intervention (up to 16 weeks)
Awards & highlights

Study Summary

This trial will test whether adding protein supplements to a resistance exercise program helps pancreatic cancer patients undergoing chemotherapy to maintain or improve their skeletal muscle mass.

Who is the study for?
This trial is for adults over 18 with non-metastatic pancreatic cancer starting chemotherapy. They must understand English or Spanish, be able to exercise (not currently doing moderate/vigorous activity over 60 minutes/week), not smoke, and can travel to DFCI for check-ups. Excluded are those with uncontrolled illnesses, other cancers, or conditions preventing exercise.Check my eligibility
What is being tested?
The RE-BUILD Trial tests if resistance training (RT) combined with protein supplements improves muscle mass in pancreatic cancer patients during chemo compared to RT alone or attention control (home-based stretching).See study design
What are the potential side effects?
While the study focuses on benefits rather than side effects, potential risks may include typical exercise-related issues like muscle soreness or strain from resistance training.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can communicate in English or Spanish.
Select...
I am starting chemotherapy for my pancreatic cancer that has not spread.
Select...
I am over 18 years old.
Select...
I can start a supervised exercise program without health issues stopping me.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~evaluating change between baseline, mid-intervention, and post-intervention (up to 16 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and evaluating change between baseline, mid-intervention, and post-intervention (up to 16 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Exercise Session Attendance Rate
Protein Supplementation (PS) Rate
Secondary outcome measures
Gait Speed
Muscular Strength
Physical Fitness - Performance
+16 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Resistance Training (RT) and Protein Supplementation (PS)Experimental Treatment1 Intervention
Participants will be randomly assigned to the Resistance Training (RT) and Protein Supplementation (PS) group and receive virtually (Zoom) supervised home-based exercise program 3-days a week with daily protein supplementation for the duration of their chemotherapy with a maximum of 16-weeks of exercise. Exercises will be tailored to the participants' fitness levels. Sessions will last ~60 minutes including 5-minute warm-up and 5-minute cool-down. Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions.
Group II: Resistance Training (RT)Experimental Treatment1 Intervention
Participants will be randomly assigned to the Resistance Training (RT) group and receive virtually (Zoom) supervised home-based exercise program 3-days a week. Exercises will be tailored to the participants' fitness levels. Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions.
Group III: Attention Control (AC)Active Control1 Intervention
Participants will be randomly assigned to the Attention Control (AC) group and receive instruction on a home-based, 3 days a week stretching program. Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions. The attention control group will be given the option to participate in the exercise intervention after their treatment is completed, with a cap of a 16-week period.

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,080 Previous Clinical Trials
340,885 Total Patients Enrolled
Christina M Dieli-Conwright, PhD, MPHPrincipal InvestigatorDana-Farber Cancer Institute

Media Library

Resistance Training (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05356117 — N/A
Pancreatic Cancer Research Study Groups: Attention Control (AC), Resistance Training (RT) and Protein Supplementation (PS), Resistance Training (RT)
Pancreatic Cancer Clinical Trial 2023: Resistance Training Highlights & Side Effects. Trial Name: NCT05356117 — N/A
Resistance Training (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05356117 — N/A
~11 spots leftby Jan 2025